AKR1C3 Inhibition: A Strategy to Reverse Osimertinib Resistance in Non-small Cell Lung Cancer

Resistance to Osimertinib via the EGFR C797S mutation is a major challenge in the treatment of nonsmall cell lung cancer (NSCLC). Combining Osimertinib with <b>SG-55</b>, a novel selective AKR1C3 inhibitor, effectively reverses this resistance, restoring sensitivity in NSCLC cells with the C797S mutation. This highlights AKR1C3 inhibition in overcoming antitumor drug resistance for further preclinical investigation.